Market Research Reports and Industry Reports

Jounce Therapeutics Inc (JNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Jounce Therapeutics Inc (Jounce) is a developer of cancer immunotherapies. The companys lead candidate ICOS is an agonist monoclonal antibody which stimulates T effector cells to enhance anti-tumor activity. It harnesses its proprietary product engine to gain new insights into cancer immunotherapy and explore multiple mechanisms of action against a broad spectrum of targets. Jounce specializes in areas of tumor immunology, antibody discovery and optimization and integrated translational capabilities. The company develops immunotherapy treatments for a range of cancers and cancerous tumours. It has collaborations with the universities, general hospitals and cancer centers. Jounce is headquartered in Cambridge, Massachusetts, the US.

Jounce Therapeutics Inc (JNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

3
List of Tables 5
List of Figures 5
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Jounce Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Jounce Therapeutics Raises USD56 Million in Series B Financing 12
Jounce Therapeutics Raises US$47 Million In Series A Financing 14
Partnerships 15
OncoSec Medical Enters into Agreement with Jounce Therapeutics 15
Celgene Enters into Agreement with Jounce Therapeutics 16
Jounce Therapeutics Enters Into Research Agreement With Adimab 17
Licensing Agreements 18
Jounce Therapeutics Amends its Licensing Agreement for JTX-2011 18
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 20
Equity Offering 21
Jounce Therapeutics Prices IPO for USD101.8 Million 21
Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 23
Jounce Therapeutics Inc - Key Competitors 24
Jounce Therapeutics Inc - Key Employees 25
Jounce Therapeutics Inc - Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 09, 2017: Jounce Therapeutics Reports Second Quarter 2017 Financial Results 27
May 09, 2017: Jounce Therapeutics Reports First Quarter 2017 Financial Results 29
Mar 10, 2017: Jounce Therapeutics reports net income for Q4, provides fiscal 2017 guidance 31
Mar 10, 2017: Jounce Therapeutics reports net income for Q4 32
Corporate Communications 33
Oct 23, 2017: Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors 33
Aug 15, 2017: Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development 34
Sep 26, 2016: Jounce Therapeutics Appoints Stephen Farrand, Ph.D., to Chief Technical Officer 35
May 25, 2016: Jounce Therapeutics Appoints Barbara G. Duncan to its Board of Directors 36
Jan 21, 2016: Jounce Therapeutics Appoints Perry Karsen to Its Board of Directors 37
Product News 38
04/19/2016: Jounce Therapeutics to Deliver Keynote Address and Overview of Lead Program at PEGS Boston 2016 38
04/17/2016: Jounce Therapeutics Presents Data Highlighting Advances From Two Programs in its Immuno-Oncology Pipeline at the 2016 AACR Annual Meeting 39
Clinical Trials 40
Sep 13, 2016: Applied BioMath announces Jounce Therapeutics has selected their Team for Clinical Trial Support for the JTX-2011 ICONIC Trial 40
Mar 16, 2016: Jounce Therapeutics to Present Program Updates at AACR Annual Meeting 2016 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List Of Tables

List of Tables
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Jounce Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Jounce Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Jounce Therapeutics Raises USD56 Million in Series B Financing 12
Jounce Therapeutics Raises US$47 Million In Series A Financing 14
OncoSec Medical Enters into Agreement with Jounce Therapeutics 15
Celgene Enters into Agreement with Jounce Therapeutics 16
Jounce Therapeutics Enters Into Research Agreement With Adimab 17
Jounce Therapeutics Amends its Licensing Agreement for JTX-2011 18
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 20
Jounce Therapeutics Prices IPO for USD101.8 Million 21
Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 23
Jounce Therapeutics Inc, Key Competitors 24
Jounce Therapeutics Inc, Key Employees 25

Jounce Therapeutics Inc (JNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Jounce Therapeutics Inc (Jounce) is a developer of cancer immunotherapies. The companys lead candidate ICOS is an agonist monoclonal antibody which stimulates T effector cells to enhance anti-tumor activity. It

USD 250View Report

Jounce Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Jounce Therapeutics Inc (Jounce) is a biotechnology company. The company concentrates on the discovery and development of cancer immunotherapies, which enable the patients immune system to search for and attack

USD 250View Report

Transition Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Transition Therapeutics Inc (Transition) a subsidiary of OPKO Health Inc, is a biopharmaceutical company that develops medicines for the treatment of CNS disorders, Alzheimers disease and diabetes. The company develops

USD 250View Report

Iovance Biotherapeutics Inc (IOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Nov 2017
No. of Pages :42
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube